Figure 9.

Efficacy and safety of approved antiretroviral regimens in the treatment of treatment-naïve and virologically-suppressed adults with HIV-1 infections. (A) Clinical efficacy was defined by the proportion of patients achieving HIV-1 RNA <50 copies/mL at Week 48. Data from Table 3, Table 4 were merged to demonstrate the clinical efficacy of approved antiretroviral regimens. (B) Proportions of adverse events during the treatment of approved antiretroviral regimens in randomized clinical trials. Missing data are indicated by white-colored cells. Original data are available in Table S1.